1. Home
  2. Resources
  3. COVID-19 Therapeutics Provider Resources

COVID-19 Therapeutics Provider Resources

This webpage is specifically intended for the medical community.
Click here to find locations offering treatments.

Updates

Please review the U.S. Department of Health and Human Services for the latest guidelines regarding Monoclonal Antibody Treatments.

As it stands, Bebtelovimab, Evusheld and the Oral Antivirals are effective against the predominant strain of SARS-COV2 Omicron Variant (B.A.5). However, the FDA has advised all prescribers to monitor the Regional Variant Data Tracker when prescribing and the Antiviral Resistance information in the Healthcare Provider Fact Sheet for therapeutic resistance against SARS-CoV-2 variant in our area.

As of August 15, 2022, Bebtelovimab will be available for commercial purchase directly through AmerisourceBergen. If you have an existing account with AmerisourceBergen, you will have immediate access to purchase these treatments. Any facilities without an AmerisourceBergen account will need register for an account by contacting asdaccountsetup@amerisourcbergen.com.

Revised Emergency Use Authorization for Paxlovid

Updated Dispensing Information

About Monoclonal Antibody Therapeutic (mAb) Treatments

Overview of Monoclonal Antibody Treatments

Due to the overwhelming presence of Omicron Variant (BA.2), the U.S. Food and Drug Administration now states the monoclonal antibody treatment Sotrovimab is NOT authorized for use anywhere in the U.S. 

Lilly’s Bebtelovimab
Type: Monoclonal Antibody
Ordering: Now available for commercial purchase on AmerisourceBergen
Administered: Intravenous – Treatment for mild to moderately ill outpatients and post-exposure prophylaxis
Target Population: Exposed individuals that are at high risk for progression to severe COVID-19 symptoms. Effective against the omicron variant and sub-lineages.

AstraZeneca’s Evusheld (AZD7442)
Type: Monoclonal Antibody and Pre-Exposure Prophylaxis
Minimum Order Requirements: 24 Courses per Case
Target Population: For individuals who have moderate to severe immunocompromised states and are not expected to mount an adequate response to vaccination or individuals for whom COVID-19 vaccination is contraindicated due to severe adverse reaction to vaccine. Must be at high risk for progression to severe COVID-19 symptoms. CDPH Picks facilities that will receive treatments.

Test to Treat

Overview of Test to Treat

The Test to Treat initiative is a program created by the federal government to bridge the gap between patients testing positive and receiving oral antiviral medication. The only treatments available in the Test to Treat program are Merck’s Lagevrio (Molnupiravir) and Pfizer’s Paxlovid.  This initiative will also expand access and attempt to tackle equity discrepancies throughout the United States.

To locate Test to Treat sites near you please view COVID-19 Test to Treat Locator.

You may be eligible to become a Test to Treat facility if you meet the following criteria listed below:

  1. Offer services to all individuals, regardless of insurance status or ability to pay.
  2. The ability to conduct rapid COVID-19 testing on-site (result available at time of visit) or provide an evaluation of at-home testing results.
  3. Have available health care providers to provide timely and thorough assessments, consistent with FDA requirements regarding these therapeutic options.
  4. Have a co-located pharmacy to readily dispense oral medications to eligible patients in a timely manner.

For more information please refer to the Fact Sheet: COVID-19 Test to Treat.

Once you confirm your facility meets all the criteria listed above you can fill out the Test to Treat Program Interest form.

If you have any additional questions you can reach out to your Local Health Jurisdiction at SBCOVID19Therapetics@dph.sbcounty.gov.

Oral Antiviral Medication

The CDC has issued a Health Alert Network Health Advisory to update the healthcare providers and public health departments of the potential for recurrence of COVID-19 or COVID-19 rebound. Although, Paxlovid remains the first recommendation for early stage treatment of mild to moderate COVID-19 among persons at high risk for progression to severe disease.

COVID-19 rebound has been reported between 2-8 days after initial recovery and is characterized by the recurrence of COVID-19 symptoms or a new positive viral test after having tested negative. Current data has not shown any signs of severe disease or that an additional dose of Paxlovid is needed.

Healthcare providers are encouraged to report cases of COVID-19 rebound after Paxlovid treatment to Pfizer using Pfizer Safety Reporting and to FDA MedWatch.

Please refer to Official CDC Health Advisory for Paxlovid

Pfizer’s Paxlovid
Type:
Oral antiviral
Minimum Order Requirement: 20 Courses
Target Population: COVID-19 patients 12 years of age and older with mild-moderate symptoms and are at high risk of developing severe COVID-19, including hospitalization or death.

Pfizer’s Renal Paxlovid
Type: Modified Dosing for the Oral Antiviral Paxlovid
Minimum Order Requirement: 5 Courses
Target Population: COVID-19 patients with moderate renal impairment, 12 years of age and older with mild-moderate symptoms and are at high risk of developing severe COVID-19, including hospitalization or death.

Renal Dosing Letter for Health Care Providers

Lagevrio (Molnupiravir)
Type: Oral Antiviral
Minimum Order Requirement: 20 Courses
Target Population: Adult COVID-19 patients with mild-moderate symptoms and are at high risk of developing severe COVID-19, including hospitalization or death. Also used for those who do not fall under the FDA authorization of alternative COVID-19 treatment options.

Providers should carefully review the fact sheet for healthcare providers (available both for Paxlovid and Lagevrio (Molnupiravir)) before prescribing either medication to ensure that the patient’s condition warrants treatment, that there are no drug interactions, and that there are contraindications to therapy.

Providers Eligible to Receive Therapeutics

Bebtelovimab: Providers must have the ability to administer (intravenously) and properly store Monoclonal Antibodies Treatments. All new providers must be reviewed and approved by the San Bernardino County’s Public Health Officer and Therapeutics Team. After approval, you will begin the onboarding process for activating a Health Partner Order Portal (HPOP) account.

Evusheld: Evusheld is the only known Pre-Exposure Prophylaxis (preventative) treatment. If you would like to administer Evusheld at your facility, please be sure to review the EUA. In a similar process to all other Monoclonal Antibodies, you must be approved by the San Bernardino County’s Public Health Officer and Therapeutics Team. Once approved and you have confirmed you can administer this medication as authorized by the FDA you will be on boarded for a Health Partner Order Portal (HPOP) account.

Paxlovid and Lagevrio (Molnupiravir): Paxlovid and Lagevrio (Molnupiravir) are currently available at select federal retail pharmacies and providers throughout San Bernardino County. Other providers are able to request these treatments using the Therapeutic Treatment Request Form.

Follow the link below for lists of all pharmacies that have received these products.

COVID-19 Therapeutics Locator

How to Order Treatments

Please note: treatment requests are not guaranteed to be allocated. Allocation decisions are made based on guidelines, amount received from the state, and necessity of the community.

All therapeutics that are currently available can be requested directly from San Bernardino County via COVID-19 Therapeutics Treatment Request Form. Please note requests are not guaranteed.

If you have not been contacted for a therapeutic treatment of interest please fill out the County Interest form to inquire more details about your request.

Reporting Requirements

Reporting for ALL COVID Therapeutics

All COVID-19 Therapeutics must be reported every Monday and Thursday by 11:59 p.m. All reporting is done within HPOP system. The submission of these utilization reports are a determining factor for future allocations of therapeutics given to the county. Please review the flyer below for further step by step guidance on how to report your inventory.

Accounts that are not showing in compliance with reporting will not receive COVID-19 Therapeutics until their HPOP inventory is corrected.